Post by Johnson & Johnson Innovative Medicine

#NEWS Today, we announced that we have entered into an agreement to acquire Firefly Bio, a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform. The Firelink™ DAC platform for KRAS-driven tumors is a novel approach to overcome limitations of existing therapies, with the potential to deliver more effective, durable treatment options. For more than three decades, Johnson & Johnson has advanced innovative therapies to address some of the most complex cancers and improve outcomes for patients worldwide. This acquisition strengthens our oncology pipeline and advances our ambition to develop medicines for the most prevalent and hard-to-treat cancers. Learn more: https://lnkd.in/erA6mWap #JNJOncology #Growth #Innovation